Comparison of tolvaptan treatment between patients with the SIADH and congestive heart failure: a single-center experience
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background/Aims: Tolvaptan is a very effective treatment for hypervolemic or euvolemic hyponatremia. We compared the clinical efficacy of and response to tolvaptan in patients with the syndrome of inappropriate antidiuretic hormone secretion (SIADH) and congestive heart failure (CHF). Methods: We retrospectively reviewed the medical records of 50 patients (SIADH, n = 30; CHF, n = 20) who were prescribed tolvaptan between July 2013 and October 2015. Tolvaptan was prescribed when the serum sodium level was < 125 mmol/L and the standard treatment failed. Normonatremia was defined as a serum sodium level of > 135 mmol/L. Results: After the initiation of tolvaptan therapy, there was an immediate response in the urine volume and serum sodium level in all patients. The improvements in the urine volume and serum sodium concentration were highest within the first 24 hours of treatment. In addition, the mean change in the serum sodium level during the first 24 hours was significantly higher in patients with SIADH than in those with CHF (ΔNa, 9.9 ± 4.5 mmol/L vs. 6.9 ± 4.4 mmol/L, respectively; p = 0.025). Also, the mean maintenance dose was lower, and the total duration of tolvaptan use was slightly shorter in the SIADH group than CHF group (21.5 ± 14.9 days vs. 28.0 ± 20.1 days, p = 0.070). Conclusions: The early response to tolvaptan treatment was better in patients with SIADH than in those with CHF. Thus, the tolvaptan treatment strategy should be differed between patients with SIADH and those with CHF.
Abstract
Background/Aims: Tolvaptan is a very effective treatment for hypervolemic or euvolemic hyponatremia. We compared the clinical efficacy of and response to tolvaptan in patients with the syndrome of inappropriate antidiuretic hormone secretion (SIADH) and congestive heart failure (CHF). Methods: We retrospectively reviewed the medical records of 50 patients (SIADH, n = 30; CHF, n = 20) who were prescribed tolvaptan between July 2013 and October 2015. Tolvaptan was prescribed when the serum sodium level was < 125 mmol/L and the standard treatment failed. Normonatremia was defined as a serum sodium level of > 135 mmol/L. Results: After the initiation of tolvaptan therapy, there was an immediate response in the urine volume and serum sodium level in all patients. The improvements in the urine volume and serum sodium concentration were highest within the first 24 hours of treatment. In addition, the mean change in the serum sodium level during the first 24 hours was significantly higher in patients with SIADH than in those with CHF (ΔNa, 9.9 ± 4.5 mmol/L vs. 6.9 ± 4.4 mmol/L, respectively; p = 0.025). Also, the mean maintenance dose was lower, and the total duration of tolvaptan use was slightly shorter in the SIADH group than CHF group (21.5 ± 14.9 days vs. 28.0 ± 20.1 days, p = 0.070). Conclusions: The early response to tolvaptan treatment was better in patients with SIADH than in those with CHF. Thus, the tolvaptan treatment strategy should be differed between patients with SIADH and those with CHF.
참고문헌 (20)
- Upadhyay A, "Incidence and prevalence of hyponatremia", Am J Med, 119(7 Suppl 1), pp.S30~S35 (2006)[DOI]
- 김효상, "입원 환자에서 발생한 중증 저나트륨혈증의 임상상 및 경과 분석; 간질환 유무에 따른 비교", Kidney Research and Clinical Practice, 27(6), pp.678~687 (2008), 대한신장학회
- Gross P, "Treatment of severe hyponatremia: conventional and novel aspects", J Am Soc Nephrol, 12(Suppl 17), pp.S10~S14 (2001)
- Verbalis JG, "Hyponatremia treatment guidelines 2007: expert panel recommendations", Am J Med, 120(11 Suppl 1), pp.S1~S21 (2007)
- Gheorghiade M, "Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial", Arch Intern Med, 167, pp.1998~2005 (2007)[DOI]
- Waikar SS, "Mortality after hospitalization with mild, moderate, and severe hyponatremia", Am J Med, 122, pp.857~865 (2009)[DOI]
- Zilberberg MD, "Epidemiology, clinical and economic outcomes of admission hyponatremia among hospitalized patients", Curr Med Res Opin, 24, pp.1601~1608 (2008)[DOI]
- Peri A, "Clinical review: the use of vaptans in clinical endocrinology", J Clin Endocrinol Metab, 98, pp.1321~1332 (2013)[DOI]
- Schrier RW, "Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia", N Engl J Med, 355, pp.2099~2112 (2006)[DOI]
- Nemerovski C, "Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review", Clin Ther, 32, pp.1015~1032 (2010)[DOI]
- Verbalis JG, "Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion", Eur J Endocrinol, 164, pp.725~732 (2011)[DOI]
- Imamura T, "Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients: association between non-responders and chronic kidney disease", Circ J, 77, pp.397~404 (2013)[DOI]
- Narayen G, "Vasopressin receptor antagonists and their role in clinical medicine", Indian J Endocrinol Metab, 16, pp.183~191 (2012)[DOI]
- Berl T, "Oral tolvaptan is safe and effective in chronic hyponatremia", J Am Soc Nephrol, 21, pp.705~712 (2010)[DOI]
- Klein L, "Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study", Circulation, 111, pp.2454~2460 (2005)[DOI]
- Konstam MA, "Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial", JAMA, 297, pp.1319~1331 (2007)[DOI]
- Gheorghiade M, "Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial", Circulation, 107, pp.2690~2696 (2003)[DOI]
- Garcha AS, "Review of tolvaptan in the treatment of hyponatremia", Clin Med Insights Ther, 3, pp.315~325 (2011)
- Ramires FJ, "Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy", Am J Cardiol, 85, pp.1207~1211 (2000)[DOI]
- Shoaf SE, "In vitro P-glycoprotein interactions and steady-state pharmacokinetic interactions between tolvaptan and digoxin in healthy subjects", J Clin Pharmacol, 51, pp.761~769 (2011)[DOI]